Allogene Therapeutics (ALLO) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Allogene Therapeutics (ALLO) has outperformed REGENXBIO (RGNX) over the past year, gaining 5.9% versus a loss of 27.7%. Over five years, RGNX leads with a -78.9% price change compared with -91.3% for ALLO. REGENXBIO is the larger company by market cap ($501.4 million vs $494.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | RGNX |
|---|---|---|
| Share price | $1.43 | $7.60 |
| Market cap | $494.05M | $501.37M |
| 1-day change | -2.05% | +1.95% |
| YTD return | +4.38% | -47.26% |
| 1-year return | +5.93% | -27.74% |
| 5-year return | -91.32% | -78.87% |
| EPS (TTM) | $-0.66 | $-3.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.46 | $16.19 |
| 52-week low | $1.04 | $5.46 |
| Distance from 52-week high | -67.94% | -53.09% |
| Analyst consensus | none | buy |
| Avg. price target upside | +529.37% | +210.47% |
| Average volume | 5.78M | 1.53M |
| Shares outstanding | 345.49M | 66.01M |
| Employees | 150 | 371 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLO has outperformed RGNX by 33.7 percentage points over the past year.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Healthcare · Biotechnology · 150 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Healthcare · Biotechnology · 371 employees
ALLO vs RGNX FAQ
Which is bigger, Allogene Therapeutics or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $501.37M compared with $494.05M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or RGNX?
ALLO returned +5.93% over the past 12 months, compared with -27.74% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and REGENXBIO in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.